These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30673082)

  • 21. Administrative Burden and Costs of Prior Authorizations in a Dermatology Department.
    Carlisle RP; Flint ND; Hopkins ZH; Eliason MJ; Duffin KC; Secrest AM
    JAMA Dermatol; 2020 Oct; 156(10):1074-1078. PubMed ID: 32845288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication Access in America and Medicare Part D: Prescription Shopping Saves but May Be Costly.
    Upchurch G; Disco ME; Visco JL; Huffman KF
    J Am Geriatr Soc; 2018 Jan; 66(1):33-40. PubMed ID: 29124745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Appropriate off-label prescription in practice].
    Augustin M
    Hautarzt; 2013 Oct; 64(10):728-35. PubMed ID: 24150820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid Prescribing Patterns and Complications in the Dermatology Medicare Population.
    Cao S; Karmouta R; Li DG; Din RS; Mostaghimi A
    JAMA Dermatol; 2018 Mar; 154(3):317-322. PubMed ID: 29417134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical audit of high-cost and off-label drug use in dermatology.
    Ong N; McMeniman E; Pillans P; Soyer HP
    Australas J Dermatol; 2017 Feb; 58(1):30-34. PubMed ID: 26344939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rising drug costs: the impact on dermatology.
    Rico MJ
    Skin Therapy Lett; 2000; 5(4):1-2,5. PubMed ID: 10785406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.
    Albrecht J; Adamson AS; Barbieri JS; Bennett DD; Kiracofe EA; Kourosh AS; Leslie KS; Merola JF; Nguyen J; Siegfried E; Strickland N; Olbricht S; Asgari MM;
    J Am Acad Dermatol; 2019 Feb; 80(2):577-578. PubMed ID: 30244066
    [No Abstract]   [Full Text] [Related]  

  • 29. Off-label use reimbursement.
    Cohen J; Wilson A; Faden L
    Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.
    França K; Litewka S
    Int J Dermatol; 2019 Jul; 58(7):788-794. PubMed ID: 30168846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential impact of Medicare Part D in the end-stage renal disease population.
    St Peter WL
    Adv Chronic Kidney Dis; 2008 Apr; 15(2):140-6. PubMed ID: 18334238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
    Conti RM; Bernstein AC; Villaflor VM; Schilsky RL; Rosenthal MB; Bach PB
    J Clin Oncol; 2013 Mar; 31(9):1134-9. PubMed ID: 23423747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical setting influences off-label and unlicensed prescribing in a paediatric teaching hospital.
    Czarniak P; Bint L; Favié L; Parsons R; Hughes J; Sunderland B
    PLoS One; 2015; 10(3):e0120630. PubMed ID: 25756896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-sectional survey of off-label and unlicensed prescribing for inpatients at a paediatric teaching hospital in Western Australia.
    Landwehr C; Richardson J; Bint L; Parsons R; Sunderland B; Czarniak P
    PLoS One; 2019; 14(1):e0210237. PubMed ID: 30620749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
    Czaja AS; Valuck R
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label use in dermatology in Germany: what has changed since 2004.
    Brockmeyer NH; Brucklacher U; Potthoff A; Reich-Schupke S
    J Dtsch Dermatol Ges; 2009 Nov; 7(11):938-45. PubMed ID: 19386019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications.
    Dos Santos L; Heineck I
    Farm Hosp; 2012; 36(4):180-6. PubMed ID: 22030161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
    DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
    JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.